



Clinical Updates in Breast Cancer From San Antonio

Clinical Update 3 – Neoadjuvant/Adjuvant Pembrolizumab for HR+/HER2– EBC: Results From the Phase 3 KEYNOTE-756 Trial

References

Tweet 2 References:

Cardoso F, O'Shaughnessy J, McArthur H, et al. (GS01-02) Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2– breast cancer: KEYNOTE-756. Presented at: SABCS; December 5–9 2023; San Antonio, TX. Accessed December 6, 2023.

<https://sabcs2023.eventscribe.net/fsPopup.asp?PresentationID=1329787&query=merck&Mode=presInfo>

Cardoso F, McArthur HL, Schmid P, et al. LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer. *Ann Oncol*. 2023;34:S1260-S1261. doi:10.1016/j.annonc.2023.10.011

Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. *N Engl J Med*. 2020;382(9):810-821. doi:10.1056/NEJMoa1910549

Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. *N Engl J Med*. 2022;386(6):556-567. doi:10.1056/NEJMoa2112651

Glossary

AE, adverse event
Chemo, chemotherapy
EBC, early breast cancer
EFS, event-free survival
ER, estrogen receptor
ETNBC, early triple-negative breast cancer
HER2–, human epidermal growth factor receptor 2 negative
HR+, hormone receptor positive
irAE, immune-related adverse event
LN, lymph node
Neo/adj, neoadjuvant/adjuvant
pCR, pathologic complete response
PD-L1, programmed death-ligand 1
pembro, pembrolizumab
TNBC, triple-negative breast cancer
TRAE, treatment-related adverse event
w/, with